But this month, Cingulate was able to reinstate those executives’ annual base salaries. CEO Shane Schaffer’s annual base salary is back to $503,000, COO Laurie Myer’s salary is $424,000, and ...

At Tuesday's close, Cingulate shares fell 4.99% to $3.62 and slipped further 1.66% to $3.56 in after-hours trading. According to the Kansas-based biotech, children who took CTx-1301 at doses of 18 ...

It follows the announcement that Cingulate has been granted European Patent No. 3261625 for its flagship asset, CTx-1301, which is designed to treat Attention Deficit Hyperactivity Disorder (ADHD).

KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its ...

Cingulate (CING) signed a joint commercialization agreement with Indegene for its lead drug candidate CTx-1301 to treat attention deficit/hyperactivity disorder ((ADHD)).Cingulate said ...